End-of-day quote
Korea S.E.
03:30:00 30/04/2024 am IST
|
5-day change
|
1st Jan Change
|
15,670
KRW
|
+1.10%
|
|
+2.82%
|
+7.48%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
4,44,868
|
2,76,877
|
6,81,166
|
5,61,830
|
2,78,859
|
2,33,568
|
Enterprise Value (EV)
1 |
3,97,811
|
2,41,559
|
6,27,582
|
5,60,684
|
2,60,984
|
2,47,001
|
P/E ratio
|
-51.2
x
|
-19.2
x
|
-34.1
x
|
-18.9
x
|
-14.3
x
|
-11
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1,473
x
|
245
x
|
275
x
|
153
x
|
29.9
x
|
13.7
x
|
EV / Revenue
|
1,317
x
|
214
x
|
254
x
|
153
x
|
28
x
|
14.5
x
|
EV / EBITDA
|
-51.5
x
|
-16.8
x
|
-41.6
x
|
-23.6
x
|
-12.9
x
|
-15.9
x
|
EV / FCF
|
-59.7
x
|
-37.1
x
|
-85.3
x
|
-64.8
x
|
-13.3
x
|
-6.93
x
|
FCF Yield
|
-1.68%
|
-2.7%
|
-1.17%
|
-1.54%
|
-7.52%
|
-14.4%
|
Price to Book
|
8.1
x
|
6.62
x
|
15
x
|
30.3
x
|
4.33
x
|
4.73
x
|
Nbr of stocks (in thousands)
|
13,008
|
13,060
|
13,542
|
13,703
|
13,703
|
16,020
|
Reference price
2 |
34,200
|
21,200
|
50,300
|
41,000
|
20,350
|
14,580
|
Announcement Date
|
29/03/19
|
12/03/20
|
15/03/21
|
15/03/22
|
15/03/23
|
14/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
302
|
1,130
|
2,474
|
3,674
|
9,320
|
17,064
|
EBITDA
1 |
-7,726
|
-14,341
|
-15,101
|
-23,794
|
-20,301
|
-15,543
|
EBIT
1 |
-8,234
|
-15,117
|
-16,241
|
-25,424
|
-22,376
|
-18,185
|
Operating Margin
|
-2,726.47%
|
-1,337.38%
|
-656.41%
|
-691.92%
|
-240.07%
|
-106.57%
|
Earnings before Tax (EBT)
1 |
-7,742
|
-14,244
|
-20,511
|
-31,099
|
-29,108
|
-18,170
|
Net income
1 |
-7,742
|
-14,353
|
-19,385
|
-29,715
|
-19,495
|
-19,102
|
Net margin
|
-2,563.58%
|
-1,269.79%
|
-783.44%
|
-808.7%
|
-209.17%
|
-111.94%
|
EPS
2 |
-667.5
|
-1,102
|
-1,474
|
-2,171
|
-1,423
|
-1,324
|
Free Cash Flow
1 |
-6,667
|
-6,512
|
-7,354
|
-8,649
|
-19,635
|
-35,664
|
FCF margin
|
-2,207.69%
|
-576.15%
|
-297.23%
|
-235.4%
|
-210.67%
|
-209%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
29/03/19
|
12/03/20
|
15/03/21
|
15/03/22
|
15/03/23
|
14/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
13,433
|
Net Cash position
1 |
47,057
|
35,318
|
53,584
|
1,145
|
17,876
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-0.8642
x
|
Free Cash Flow
1 |
-6,667
|
-6,512
|
-7,354
|
-8,649
|
-19,635
|
-35,664
|
ROE (net income / shareholders' equity)
|
-21%
|
-29.7%
|
-44.5%
|
-93.5%
|
-65.7%
|
-32.8%
|
ROA (Net income/ Total Assets)
|
-13.3%
|
-18.7%
|
-16.4%
|
-19.2%
|
-12.8%
|
-9.65%
|
Assets
1 |
58,128
|
76,598
|
1,18,193
|
1,54,513
|
1,52,874
|
1,97,875
|
Book Value Per Share
2 |
4,223
|
3,200
|
3,344
|
1,352
|
4,700
|
3,084
|
Cash Flow per Share
2 |
216.0
|
379.0
|
837.0
|
2,506
|
360.0
|
748.0
|
Capex
1 |
500
|
1,007
|
786
|
1,290
|
2,233
|
8,826
|
Capex / Sales
|
165.69%
|
89.08%
|
31.79%
|
35.11%
|
23.96%
|
51.72%
|
Announcement Date
|
29/03/19
|
12/03/20
|
15/03/21
|
15/03/22
|
15/03/23
|
14/03/24
|
|
1st Jan change
|
Capi.
|
---|
| +7.48% | 187M | | -1.65% | 104B | | +6.75% | 97.47B | | +5.71% | 22.25B | | -12.60% | 21.68B | | -9.70% | 18.2B | | -39.98% | 17.02B | | -10.17% | 16.36B | | +6.12% | 14.39B | | +35.47% | 12.37B |
Bio Therapeutic Drugs
|